Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS

The homogentisic acid‐lowering therapy nitisinone is being evaluated for the treatment of alkaptonuria (AKU) at the National Centre for AKU. Beyond hypertyrosinemia, the wider metabolic consequences of its use are largely unknown. The aim of this work was to evaluate the impact of nitisinone on the serum metabolome of patients with AKU after 12 and 24 months of treatment.

• Publication year

  2019

• Venue

  JIMD Reports

• Publication date

  2019-05-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/jmd2.12042PMID 31392115PMCID 6606987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS

  2019cited by this paper
• A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.

  2019cited by this paper
• Serum Amino Acid Profiling in Patients with Alkaptonuria Before and After Treatment with Nitisinone.

  2018cited by this paper
• Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre.

  2018cited by this paper
• Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.

  2018cited by this paper
• Assessment of the Effect of Once Daily Nitisinone Therapy on 24-h Urinary Metadrenalines and 5-Hydroxyindole Acetic Acid Excretion in Patients with Alkaptonuria After 4 Weeks of Treatment.

  2018cited by this paper
• 4-Hydroxybenzaldehyde accelerates acute wound healing through activation of focal adhesion signalling in keratinocytes

  2017cited by this paper
• Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans

  2017cited by this paper
• Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health

  2017cited by this paper
• Cartilage biomarkers in the osteoarthropathy of alkaptonuria reveal low turnover and accelerated ageing

  2017cited by this paper
• Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients.

  2017cited by this paper
• The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool

  2017cited by this paper
• Potential functional and pathological side effects related to off-target pharmacological activity.

  2017cited by this paper
• From Weed Killer to Wonder Drug.

  2017cited by this paper
• Urinary Metabolomic Approach Provides New Insights into Distinct Metabolic Profiles of Glutamine and N-Carbamylglutamate Supplementation in Rats

  2016cited by this paper
• Acute fatal metabolic complications in alkaptonuria

  2016cited by this paper
• Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice

  2016cited by this paper
• Untargeted UPLC-MS Profiling Pipeline to Expand Tissue Metabolome Coverage: Application to Cardiovascular Disease

  2015cited by this paper
• Metabolic Effects of Increasing Doses of Nitisinone in the Treatment of Alkaptonuria.

  2015influential reference
• Investigating the Robustness and Diagnostic Potential of Extracellular Matrix Remodelling Biomarkers in Alkaptonuria.

  2015cited by this paper
• Relationship Between Serum Concentrations of Nitisinone and Its Effect on Homogentisic Acid and Tyrosine in Patients with Alkaptonuria.

  2015cited by this paper
• Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome.

  2015cited by this paper
• Outcome of children with hereditary tyrosinaemia following newborn screening

  2015cited by this paper
• Oxidative stress and mechanisms of ochronosis in alkaptonuria.

  2015cited by this paper
• Amyloidosis, Inflammation, and Oxidative Stress in the Heart of an Alkaptonuric Patient

  2014influential reference
• G Protein-Coupled Estrogen Receptor-1 Is Involved in the Protective Effect of Protocatechuic Aldehyde against Endothelial Dysfunction

  2014cited by this paper
• Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria afte

  2014cited by this paper
• Salvianolic acid B inhibits atherogenesis of vascular cells through induction of Nrf2-dependent heme oxygenase-1.

  2014cited by this paper
• Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone

  2013cited by this paper
• Recent advances in management of alkaptonuria (invited review; best practice article)

  2013cited by this paper
• Protocatechuic aldehyde inhibits migration and proliferation of vascular smooth muscle cells and intravascular thrombosis.

  2012cited by this paper
• Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I.

  2011cited by this paper
• Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis

  2011cited by this paper
• A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.

  2011cited by this paper
• Novel Benzo[d]-imidazole-2(3H)-thiones as Potent Inhibitors of the α-Melanocyte Stimulating Hormone Induced Melanogenesis in Melanoma B16 Cells.

  2011cited by this paper
• Novel benzo[d]imidazole-2(3H)-thiones as potent inhibitors of the alpha-melanocyte stimulating hormone induced melanogenesis in melanoma B16 cells.

  2010cited by this paper
• Proteomic and redox‐proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes

  2010cited by this paper
• Redox regulation of gamma-glutamyl transpeptidase.

  2009cited by this paper
• Use of nitisinone in patients with alkaptonuria.

  2005cited by this paper
• N-acetyl-L-tyrosine as a tyrosine source in adult parenteral nutrition.

  2003cited by this paper
• Natural history of alkaptonuria.

  2002cited by this paper
• Tyrosinemia type II: nine cases of ocular signs and symptoms.

  2001cited by this paper
• Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.

  1992cited by this paper
• Transport of gamma-glutamyl amino acids: role of glutathione and gamma-glutamyl transpeptidase.

  1979cited by this paper
• Aromatic Acids in Urine of Healthy Infants, Persistent Hyperphenylalaninemia, and Phenylketonuria, before and after Phenylalanine Load

  1974cited by this paper
• TRANSAMINATIONS BETWEEN AMINO ACIDS AND KETO ACIDS ELEVATED IN PHENYLKETONURIA AND MAPLE SYRUP URINE DISEASE

  1973cited by this paper

• Omics and rare diseases: challenges, applications, and future perspectives

  2025cites this paper
• Targeted and untargeted urinary metabolomics of alkaptonuria patients using ultra high-performance liquid chromatography-tandem mass spectrometry.

  2025cites this paper
• Alkaptonuria with Fracture Neck of Femur – A Case Report

  2024cites this paper
• Case report: Thoracolumbar spinal stenosis associated with alkaptonuria

  2023influential citation
• Alkaptonuria - Past, present and future.

  2023cites this paper
• Alcaptonuria, ocronosis y artropatía ocronótica

  2022cites this paper
• Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria

  2022cites this paper
• Long-term follow-up of alkaptonuria patients: single center experience

  2022cites this paper
• Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria

  2022cites this paper
• Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways

  2022cites this paper
• Alcaptonurie, ochronose et rhumatisme ochronotique

  2022cites this paper
• Effects of Acute and Chronic Resistance Exercise on the Skeletal Muscle Metabolome

  2021cites this paper
• Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism

  2021cites this paper
• Studies in alkaptonuria reveal new roles beyond drug clearance for phase I and II biotransformations in tyrosine metabolism

  2020cites this paper
• Title: Studies in alkaptonuria reveal new roles beyond drug clearance for phase I and II biotransformations in tyrosine metabolism. Running title: New roles for phase I and II biotransformations beyond drug clearance

  2020cites this paper
• Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS

  2019cites this paper